Lv62
1950 积分 2023-12-21 加入
OP0201 ACHIEVEMENT OF LOW DISEASE ACTIVITY AND REMISSION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH DAPIROLIZUMAB PEGOL: 48-WEEK RESULTS FROM A PHASE 3 TRIAL
24天前
已关闭
POS0734 DAPIROLIZUMAB PEGOL DEMONSTRATED SIGNIFICANT IMPROVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY: EFFICACY AND SAFETY RESULTS OF A PHASE 3 TRIAL
24天前
已关闭
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial
24天前
已完结
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial
24天前
已完结
S90 FRONTIER-3: a randomized, phase 2a study to evaluate the efficacy and safety of tozorakimab (an anti-interleukin-33 monoclonal antibody) in early-onset asthma
1个月前
已关闭
Alopecia areata: Time for position statement to include new systemic therapeutic advances
1个月前
已完结
Human kallikrein 2: A novel lineage-specific surface target in prostate cancer
1个月前
已完结
The Clinical and Molecular Response of Pyoderma Gangrenosum to Interleukin 23 Blockade: Result from a proof-of-concept open-label clinical trial
1个月前
已关闭
sKL/mKL Transcript Ratio and Protein Localization Define a Species- and Region-Specific Klotho Signature in the CNS and AD Progression
1个月前
已完结
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics
1个月前
已完结
皖公网安备34019202002308
